CRY2 and hepatocellular carcinoma: In contrast, CRY2 immunoreactivity showed a 26% increase in the DG of TPL-trained mice compared to HCC mice (Cohen’s d = 0.89; effect-size r = 0.41), which was at the border of significance (p = 0.09).